Clinical research

EXCELLA™ First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions

EuroInterv.2008;4:53-58.

J Costa Júnior
J. Ribamar Costa Jr1, MD; Alexandre Abizaid1*, MD, PhD; Fausto Feres1, MD, PhD; Ricardo Costa1, MD; Ana Cristina Seixas1, MD; Felipe Maia1, MD; Andrea Abizaid1, MD, PhD; Luis Fernando Tanajura1, MD, PhD; Rodolfo Staico1, MD; Dimytri Siqueira1, MD; Lynn Meredith2, Vinayak Bhat, PhD; John Yan2; John Ormiston3, MD; Amanda G.M.R. Sousa1, MD, PhD; Peter Fitzgerald4, MD, PhD; J. Eduardo Sousa1, MD, PhD
1. Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; 2. Elixir Medical, Sunnyvale, California, USA; 3. Auckland City Hospital, Auckland, New Zealand; 4. Stanford University Medical Center, Stanford, California, USA

Aims: First generation DES have markedly reduced restenosis. However, there is a major interest in developing new DES with greater flexibility, radiopacity and safety profile. The Elixir Me

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

clinical researchnovolimusfirst-in-manpci
Read next article
Biodegradable-polymer-based, sirolimus-eluting Supralimus® stent: 6-month angiographic and 30-month clinical follow-up results from the Series I prospective study

Latest news